iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

Segment Reporting (Tables)

3 Months Ended

Sep. 30, 2017

Schedule of Segment Reporting Information, by Segment [Table Text Block]

These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.

Three Months Ended September 30, 2017 (in thousands)	iBio, Inc.		iBio CDMO		Eliminations		Total

Revenues - external customers	$	84	$	38	$	-	$	122
Revenues – intersegment		301		210		(511)		-
Research and development		618		484		(117)		985
General and administrative		1,099		1,698		(299)		2,498
Operating loss		(1,332)		(2,029)		-		(3,361)
Interest expense		-		(480)		-		(480)
Interest and other income		12		2		-		14
Consolidated net loss		(1,321)		(2,506)		-		(3,827)
Total assets		18,810		27,485		(12,862)		33,433
Fixed assets, net		7		25,261		-		25,268
Intangible assets, net		1,757		-		-		1,757
Depreciation expense		1		337		-		338
Amortization of intangible assets		85		-		-		85

Three Months Ended September 30, 2016 (in thousands)	iBio, Inc.		iBio CDMO		Eliminations		Total

Revenues - external customers	$	86	$	49	$	-	$	135
Revenues – intersegment		152		182		(334)		-
Research and development		684		321		(185)		820
General and administrative		1,347		1,271		(149)		2,469
Operating loss		(1,793)		(1,361)		-		(3,154)
Interest expense		-		(483)		-		(483)
Interest and other income		18		7		-		25
Consolidated net loss		(1,775)		(1,837)		-		(3,612)
Total assets		11,810		36,330		(49)		48,091
Fixed assets, net		8		25,572		-		25,580
Intangible assets, net		2,023		-		-		2,023
Depreciation expense		1		323		-		324
Amortization of intangible assets		88		-		-		88